Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Year: 2022
Type: article
Source: Blood
Authors: Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar
Institutions: Memorial Sloan Kettering Cancer Center, Colorado Blood Cancer Institute, Stanford Medicine, Stanford University, Vanderbilt University Medical Center, Medical College of Wisconsin, CHRISTUS Transplant Institute, Cleveland Clinic, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, City Of Hope National Medical Center, St David's Medical Center, Allogene Therapeutics (United States), Mayo Clinic
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310108042